GlassScriptPhysician profile
Raoul Joubran
NPI 1689784373
$4,655.99
in general payments reported to CMS, 2019-2025
22 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $317 · 2021: $741 · 2022: $972 · 2023: $765 · 2024: $569 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.66 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.04 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,159.52 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $343.71 | 2019-2025 | |
| Genzyme Corporation | $336.53 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $278.73 | 2022-2025 | Dupixent |
| Pfizer INC. | $191.48 | 2019-2025 | |
| Braintree Laboratories, INC. | $120.91 | 2019 | |
| Janssen Biotech, INC. | $110.95 | 2020-2023 | Stelara, Remicade, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $108.93 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $86.50 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $79.37 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Aimmune Therapeutics, INC. | $55.38 | 2024-2025 | Zenpep |
| Mauna Kea Technologies, INC. | $50.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $34.80 | 2024 | Voquezna |
| Celgene Corporation | $29.36 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29.33 | 2025 | Omvoh |
| Ucb, INC. | $26.25 | 2019 | |
| Alfasigma USA, INC. | $20.20 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Novo Nordisk INC | $14.07 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $12.45 | 2022 | |
| Qol Medical, LLC | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raoul Joubran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.